Desvenlafaxine Tablet, Extended Release
Product Images NDC 46708-540

This is a description of extended-release tablets for Desvenlafaxine succinate, equivalent to 100mg Desvenlafaine. Each film-coated tablet is sealed and contains 152mg of medicine. The tablets should be stored between 20-25°C (68-77°F) but can be excused to 15-30°C (59-86°F) based on USP Controlled Room Temperature guidelines. The manufacturer is Alembic Pharmaceuticals Limited located in Gujarat, India, and the package includes 30 tablets to be dispensed with a medication guide. The usual dosage should be reviewed and the tablets should not be chewed, crushed, or dissolved. There is a license number GI959.*

Desvenlafaxine succinate is an active ingredient in each extended-release tablet. The tablet is film-coated and contains 38mg of the ingredient that is equivalent to 25mg of desvenlafaxine. The usual dosage information is present in the package insert. The storage temperature for the medicine should be 20° to 25°C (68° to 77°F), but it can be excursed to 15° to 30°C (59° to 86°F). Alembic Pharmaceuticals Limited manufactures the extended-release tablets. The approved NDC is 46708-542-30, and the package contains 30 unit tablets. The medication guide is to be given to each patient, and the tablets should not be crushed. No further information about the drug's uses or indications is available.*

This is a description for a medication called Desvenlafaxine, with extended-release tablets that contain 76 mg of desvenlafaxine succinate, equal to 50 mg of desvenlafaxine. The tablets come in a sealed, film-coated form and should be stored at a temperature between 20° to 25°C (68° to 77°F). The excursions are allowed to a temperature between 15° to 30°C (59° to 86°F). The manufacturer is Alembic Pharmaceuticals Limited, Panchmahal, India, and the product comes in a package of 30 tablets. A medication guide is intended to be dispensed to each patient along with the package. The usual dosage should be referred to the package insert. The Lot number is mentioned as B0, and the product is restricted for prescription use only.*

This appears to be a table or graph presenting pharmacokinetic data for a medication with differing levels of renal and hepatic impairment as well as for different populations based on gender and age. The table lists geometric mean ratios for certain measurements such as Cmax and AUC for each impairment level and population group. The medication is not specified.*

This appears to be a table or chart showing changes in Cmax (maximum plasma concentration) and AUC (area under the curve) of ketoconazole, a CYP3A4 inhibitor, compared to a reference, with values for geometric mean ratio and confidence intervals. However, without more context it is difficult to ascertain what the data is being used for or the significance of the changes.*

This appears to be a table showing estimated proportions of patients with relapse over time for a specific medication (Desvenlafaxine Extended-Release Tablets 50mg). The time to relapse is measured in days from randomization and ranges from 50 to 150 days. The estimated proportion of patients with relapse ranges from 5% to 8%.*

The text describes data related to the proportion of patients with relapse and the time to relapse for Desvenlafaxine Extended-Release Tablets compared to a placebo. The estimated proportion of patients with relapse is given as a percentage, with the values of 3, 8, 8, 3, and a degree symbol. The graph shows the time to relapse in days from randomization, with markers at 50, 100, and 150.*